FDA Approves BRIVARACETAM — ScieGen Pharmaceuticals, Inc.
On July 1, 2026, ScieGen Pharmaceuticals received FDA approval of Brivaracetam (ANDA219952), a generic oral version of the brand-name drug. This approval will likely impact the competitive landscape by fostering price competition and increasing accessibility.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day